Fortunately, over the past few years, the development of immunotherapy with ICIs and TT against kinases of the RAS/BRAF/MAPK pathway has dramatically improved its clinical outcomes, with the achievement of long-term benefit in approximately 50% of patients with metastatic disease, completely changing the perspective for melanoma patients [30,31,32]. The gene discussed is BRAF; the disease is melanoma.